About 1,298 results

ALLMedicine™ Hyperprolactinemia Center

Research & Reviews  424 results

Hyperprolactinemia after menopause: Diagnosis and management.
Maturitas Auriemma RS, Pirchio R et. al.

Aug 28th, 2021 - Most prolactinomas are diagnosed in women of reproductive age and are generally microadenomas. Prolactinomas diagnosed in postmenopausal women are less common and are not usually associated with the typical syndrome induced by prolactin excess, in...

Bu-Shen-Zhu-Yun decoction induces PRLR deubiquitination and JAK2/STAT5 activation via C...
Aging Feng H, Zhou H et. al.

Aug 24th, 2021 - To determine the effect of Bu-Shen-Zhu-Yun Decoction (BSZY-D) on the kisspeptin through JAK2/STAT5 signaling pathway in hyperprolactinemia (HPRL) infertility. SD rats were treated with BSZY-D for cerebrospinal fluid (CSF) extraction. GT1-7 cells w...

Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
https://doi.org/10.1007/s11102-021-01168-x 10.1001/jama.2016.19699 10.1007/s11102-012-0454-0 10.1210/jc.2010-0537 10.1016/j.beem.2019.101290 10.3803/EnM.2020.35.2.237 10.1210/jc.2010-1692 10.1210/jcem-60-4-698 10.1210/er.2005-9998 10.1517/14656566.1.3.555 10.1210/jcem.84.7.5810 10.1056/NEJMoa054830 10.4065/74.4.371 10.1186/s12902-020-0507-8 10.1210/clinem/dgz076 10.1210/jc.2018-02202 10.1210/jc.2008-2103 10.1007/s11102-010-0283-y 10.3171/2011.1.FOCUS10317 10.1530/EJE-07-0248 10.3803/EnM.2014.29.3.280 10.1016/j.wneu.2016.08.088 10.3171/jns.2002.97.2.0307 10.1007/s11102-019-01001-6 10.1111/j.1365-2265.2006.02493.x 10.1136/bmj.2.5816.743 10.1056/NEJM199410063311403 10.1210/jc.2009-1238 10.1210/clinem/dgaa744 10.1111/cen.13339 10.1007/s40618-020-01478-0 10.3389/fendo.2015.00085 10.1007/s11102-010-0261-4 10.1136/bcr-2017-220971 10.1530/EJE-16-0087 10.3389/fendo.2018.00636 10.1210/clinem/dgz144 10.1007/s40618-021-01569-6 10.3346/jkms.2021.36.e97 10.1210/jcem.87.7.8645 10.1055/a-1247-4908 10.1159/000180098 10.1007/s11102-019-01016-z 10.3389/fendo.2020.00439 10.1016/j.clineuro.2013.02.016 10.1007/s11102-018-0904-4 10.1007/s12020-016-1115-2
Pituitary Park JY, Choi W et. al.

Jul 1st, 2021 - Dopamine agonists (DAs) have long been the recommended first-line treatment for prolactinoma. Given the remarkable developments in surgical techniques, however, surgery is on the rise. We compared the treatment outcomes of patients with noninvasiv...

Prolactin and Other Pituitary Disorders in Kidney Disease.
Seminars in Nephrology; Huang W, Molitch ME

Jun 19th, 2021 - Prolactin levels are increased in chronic kidney disease (CKD) as a result of reduced clearance and increased secretion. Hyperprolactinemia manifests as galactorrhea and hypogonadism. Treatment of hyperprolactinemia should focus on improving bothe...

Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and net...
Journal of Clinical Pharmacy and Therapeutics; Fachi MM, de Deus Bueno L et. al.

Jun 18th, 2021 - Hyperprolactinemia is a neuroendocrine disease that is responsible for a quarter of cases of secondary amenorrhea, which can lead to infertility in women. Dopaminergic agonists (bromocriptine, cabergoline, quinagolide) can be used in the treatment...

see more →

Guidelines  2 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Endocrine Practice : Official Journal of the American Col... Samson SL, Hamrahian AH et. al.

Dec 8th, 2015 - To review the current literature regarding the prevalence of macroprolactin (macroPRL) in hyperprolactinemic patients and determine recommendations for testing. An electronic United States National Library of Medicine PubMed search (through Octobe...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  2 results

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Sep 27th, 2019 - This will be a 16-week, double blind, placebo controlled randomized trial of aripiprazole added to an existing stabilized regimen of antipsychotics (either risperidone or paliperidone oral or long acting injectable formulations) for treatment of e...

Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia

Jan 19th, 2011 - This is a 12 weeks, blind study (the patient, investigator, and sponsor do not know the study drug and dosage being taken by the patient) of the safety and tolerability of flexible-dose (3 to 12mg per day), extended-release (ER) paliperidone in co...

see more →

News  36 results

Fast Five Quiz: Sexual Disorders

Aug 11th, 2020 - Male orgasm is defined as a subjective, perceptual-cognitive event of peak sexual pleasure that in normal conditions coincides with the moment of ejaculation. Delayed ejaculation is typically a self-reported diagnosis; no firm consensus defines wh...

Fast Five Quiz: What Do You Know About Schizophrenia?

Aug 9th, 2019 - Antipsychotic medications are a mainstay of treatment, together with psychological and psychosocial inputs. These medications diminish the positive symptoms of schizophrenia and prevent relapses. If they are stopped, about 80% of patients relapse ...

DRESS Syndrome Induced by Telaprevir: A Potentially Fatal Adverse Event in Chronic Hepatitis C Therapy
Pablo Fernández-Crehuet, MD, PhD, Ricardo Ruiz-Villaverde, MD, PhD

Nov 30th, 2018 - To the Editor: A 58-year-old woman with a history of hyperprolactinemia and gastrointestinal angiodysplasia presented to the dermatology department with a generalized skin rash of 3 weeks’ duration. She did not have a history of toxic habits.

Strategies for managing medication-induced hyperprolactinemia

Mar 1st, 2018 - Less data exist on managing hyperprolactinemia that is induced by a medication other than an antipsychotic; however, it seems reasonable that the same strategies could be implemented. Specifically, for SSRI–induced hyperprolactinemia, if clinicall.

see more →